このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Evolut PRO 中国臨床試験

2026年10月29日 更新者:Medtronic Cardiovascular

Medtronic CoreValve™ Evolut™ PRO システムの中国での臨床試験

Interventional study to evaluate the safety and efficacy of the Medtronic CoreValve™ Evolut™ PRO System when used by China implanting centers in Chinese patients with severe symptomatic aortic stenosis (AS) who are at high risk for Surgical Aortic Valve Replacement (SAVR).

調査の概要

詳細な説明

The study is targeting 6 centers with a maximum of 8 centers in China and estimating 65 subjects with a maximum of up to 70 subjects with attempted implants including 50 subjects with an attempted implant in primary study population and the first two attempted subjects at each site for roll-in population. The subjects will follow the assessment with pre and post-procedure, discharge, 30 days(primary endpoint), 6 months, 1 year, and annually through 5 years.

研究の種類

介入

入学 (実際)

52

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100000
        • Chinese PLA General Hospital, Chinese PLA Medical School
      • Beijing、Beijing Municipality、中国、100000
        • Beijing Anzhen Hospital, Capital Medical University
    • Sichuan
      • Chengdu、Sichuan、中国、610000
        • West China Hospital of Sichuan University
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310009
        • The Second Affiliated Hospital Zhejiang University School of Medicine

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

65年歳以上 (高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Aortic valve area (AVA) < 1.0 cm2 (or indexed AVA <0.6 cm2/m2) OR mean gradient > 40 mmHg, OR max aortic velocity > 4.0 m/sec
  2. High risk for SAVR defined as STS-PROM score ≥ 8% AND ≤ 15%, OR documented Heart Team agreement of high risk for AVR due to frailty or comorbidities
  3. Symptoms of aortic stenosis and NYHA ≥ II

Exclusion Criteria:

  1. Age is less than 65 years old
  2. Non-calcified aortic valve
  3. Bicuspid aortic valve with no raphe or 2 raphes (Sievers classification type 0 or type 2)
  4. Ascending aortic diameter > 4.5 cm

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Medtronic CoreValve™ Evolut™ PRO System

The system comprised of the following three components:

  1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)
  2. EnVeo™ PRO Delivery Catheter System (DCS)
  3. EnVeo™ PRO Loading System (LS)

The system comprised of the following three components:

  1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)
  2. EnVeo™ PRO Delivery Catheter System (DCS)
  3. EnVeo™ PRO Loading System (LS)

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
All-cause Mortality
時間枠:30 days

All-cause mortality at 30 days

30 days
Percentage (%) of Subjects With Evaluable Echocardiograms With Moderate or Severe Aortic Regurgitation by Transthoracic Echocardiography (TTE)
時間枠:30 days

Percentage (%) of Subjects with evaluable echocardiograms with moderate or severe aortic regurgitation by transthoracic echocardiography (TTE)

30 days

二次結果の測定

結果測定
メジャーの説明
時間枠
Incidence of an VARC II Combined Composite
時間枠:30 days

Incidence of an VARC II combined composite includes the following components:

  • All-cause mortality
  • All stroke (disabling and non-disabling)
  • Life-threatening bleeding
  • Acute kidney injury: stage 2 or 3 (including renal replacement therapy)
  • Coronary artery obstruction requiring intervention
  • Major vascular complication
  • Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)
30 days
Event Rates of the Individual Components of the VARC II Composite
時間枠:30 days

Event rate of the individual components listed in the outcome

30 days
New Permanent Pacemaker Rate
時間枠:30 days

New permanent pacemaker rate

30 days
Device Success Rate
時間枠:Between 24 hours and 7 days post procedure

Device success rate:

  • Percentage of participants with absence of procedural mortality, AND
  • Percentage of participants with correct positioning of a single prosthetic heart valve into the proper anatomical location, AND
  • Percentage of participants with intended performance of the prosthetic heart valve, defined as the absence of patient-prosthesis-mismatch and mean aortic valve gradient less than 20 mmHg (or peak velocity <3m/sec), AND absence of moderate or severe prosthetic valve regurgitation
Between 24 hours and 7 days post procedure
Valve Performance Parameter - Mean Aortic Gradient
時間枠:30 days

Mean aortic gradient

30 days
Valve Performance Parameter - Effective Orifice Area
時間枠:30 days

Effective orifice area

30 days
Valve Performance Parameter -Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
時間枠:30 days

Degree of aortic regurgitation (transvalvular, paravalvular, total)

30 days

その他の成果指標

結果測定
メジャーの説明
時間枠
Event Rates of TAVI-related Complications
時間枠:30 days

Rate of the following TAVI-related complications:

  1. change to surgery
  2. need for cardiopulmonary mechanical assistance
  3. coronary occlusion or obstruction
  4. annular rupture or dissection
  5. ventricular perforation
  6. mitral valve damage
  7. prosthetic valve displacement, migration, or embolism
  8. acute kidney injury (up to 7 days post procedure)
30 days
All-cause Mortality
時間枠:6 months

Percentage of participants with all-cause mortality

6 months
All-cause Mortality
時間枠:1 year

Percentage of participants with all-cause mortality

1 year
All Stroke
時間枠:6 months

Incidence of stroke (disabling and non-disabling)

6 months
All Stroke
時間枠:1 year

Incidence of stroke (disabling and non-disabling)

1 year
Myocardial Infarction
時間枠:30 days

Incidence of MI

30 days
Myocardial Infarction
時間枠:6 months

Incidence of MI

6 months
Myocardial Infarction
時間枠:1 Year

Incidence of MI

1 Year
Incidence of Life-threatening Bleeding
時間枠:30 days

Incidence of life-threatening bleeding:

  1. Fatal bleeding (BARC type 5) OR
  2. Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR
  3. Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR
  4. Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* (BARC type 3b)
30 days
Incidence of Life-threatening Bleeding
時間枠:6 months

Incidence of life-threatening bleeding:

  1. Fatal bleeding (BARC type 5) OR
  2. Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR
  3. Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR
  4. Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* (BARC type 3b)
6 months
Incidence of Life-threatening Bleeding
時間枠:1 Year

Incidence of life-threatening bleeding:

  1. Fatal bleeding (BARC type 5) OR
  2. Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR
  3. Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR
  4. Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* (BARC type 3b)
1 Year
New AV-Conduction Disturbances (Left Bundle Branch Block (LBBB) and Right Bundle Branch Block (RBBB))
時間枠:30 days

Incidence of either LBBB or RBBB

30 days
Incidence of Prosthetic Valve Endocarditis
時間枠:30 days

Incidence of prosthetic valve endocarditis:

Any one of the following:

  1. Fulfillment of the following Duke criteria for definite endocarditis

    • Histologic and/or microbiologic evidence of infection at surgery or autopsy, or
    • 2 major criteria, or
    • 1 major criteria and 3 minor criteria, or
    • 5 minor criteria
  2. Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation

  3. Findings of abscess, pus, or vegetation involving the CoreValve™ Evolut™ PRO at autopsy

30 days
Incidence of Prosthetic Valve Endocarditis
時間枠:6 months

Incidence of prosthetic valve endocarditis:

Any one of the following:

  1. Fulfillment of the following Duke criteria for definite endocarditis

    • Histologic and/or microbiologic evidence of infection at surgery or autopsy, or
    • 2 major criteria, or
    • 1 major criteria and 3 minor criteria, or
    • 5 minor criteria
  2. Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation

  3. Findings of abscess, pus, or vegetation involving the CoreValve™ Evolut™ PRO at autopsy

6 months
Incidence of Prosthetic Valve Endocarditis
時間枠:1 Year

Incidence of prosthetic valve endocarditis:

Any one of the following:

  1. Fulfillment of the following Duke criteria for definite endocarditis

    • Histologic and/or microbiologic evidence of infection at surgery or autopsy, or
    • 2 major criteria, or
    • 1 major criteria and 3 minor criteria, or
    • 5 minor criteria
  2. Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation

  3. Findings of abscess, pus, or vegetation involving the CoreValve™ Evolut™ PRO at autopsy

1 Year
Incidence of Prosthetic Valve Thrombosis
時間枠:30 days

Incidence of Prosthetic valve thrombosis:

Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.

*Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis.

30 days
Incidence of Prosthetic Valve Thrombosis
時間枠:6 months

Incidence of Prosthetic valve thrombosis:

Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.

*Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis.

6 months
Incidence of Prosthetic Valve Thrombosis
時間枠:1 Year

Incidence of Prosthetic valve thrombosis:

Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.

*Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis.

1 Year
Valve-related Dysfunction
時間枠:1 Year

Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II)

1 Year
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
時間枠:30 days

Incidence of Valve-related dysfunction requiring repeat procedure

30 days
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
時間枠:6 months

Incidence of Valve-related dysfunction requiring repeat procedure

6 months
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
時間枠:1 Year

Incidence of Valve-related dysfunction requiring repeat procedure

1 Year
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
時間枠:1 year

Mean aortic gradient

1 year
Valve Hemodynamic Performance Metric - Effective Orifice Area
時間枠:1 year

Effective orifice area

1 year
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
時間枠:1 year

Degree of aortic regurgitation (transvalvular, paravalvular, total)

1 year
New York Heart Association (NYHA) Functional Classification
時間枠:30 days

New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest).

Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.

Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.

Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.

Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.

30 days
New York Heart Association (NYHA) Functional Classification
時間枠:6 month

New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest).

Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.

Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.

Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.

Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.

6 month
New York Heart Association (NYHA) Functional Classification
時間枠:1 Year

New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest).

Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.

Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.

Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.

Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.

1 Year
EQ-5D Quality of Life
時間枠:30 days

EuroQol Group developed this Quality of Life (QOL) questionnaire referred to as EQ-5D that includes a descriptive system comprising five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.

The answers given to ED-5D can be converted into EQ-5D index and utility scores anchored at 0 for death and 1 for perfect health.

The EQ-5D Index Score is calculated for each study participant and the descriptive statistical summary of the EQ-5D score for the study population is provided.

The EQ-5D Visual Analog Scale (VAS) Score is a scale numbered 0 to 100 (0 is the worse health the patient can imagine and 100 is the best health the patient can imagine).

30 days
EQ-5D Quality of Life
時間枠:1 Year

EuroQol Group developed this Quality of Life (QOL) questionnaire referred to as EQ-5D that includes a descriptive system comprising five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.

The answers given to ED-5D can be converted into EQ-5D index and utility scores anchored at 0 for death and 1 for perfect health.

The EQ-5D Index Score is calculated for each study participant and the descriptive statistical summary of the EQ-5D score for the study population is provided.

The EQ-5D Visual Analog Scale (VAS) Score is a scale numbered 0 to 100 (0 is the worse health the patient can imagine and 100 is the best health the patient can imagine).

1 Year
All-cause Mortality
時間枠:2 year

Percentage of participants with all-cause mortality

2 year
All Stroke
時間枠:2 year

Incidence of stroke (disabling and non-disabling)

2 year
Myocardial Infarction
時間枠:2 Year

Incidence of MI

2 Year
Incidence of Life-threatening Bleeding
時間枠:2 Year

Incidence of life-threatening bleeding:

  1. Fatal bleeding (BARC type 5) OR
  2. Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR
  3. Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR
  4. Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* (BARC type 3b)
2 Year
Incidence of Prosthetic Valve Endocarditis
時間枠:2 Year

Incidence of prosthetic valve endocarditis:

Any one of the following:

  1. Fulfillment of the following Duke criteria for definite endocarditis

    • Histologic and/or microbiologic evidence of infection at surgery or autopsy, or
    • 2 major criteria, or
    • 1 major criteria and 3 minor criteria, or
    • 5 minor criteria
  2. Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation

  3. Findings of abscess, pus, or vegetation involving the CoreValve™ Evolut™ PRO at autopsy

2 Year
Incidence of Prosthetic Valve Thrombosis
時間枠:2 Year

Incidence of Prosthetic valve thrombosis:

Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.

*Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis.

2 Year
Valve-related Dysfunction
時間枠:2 Year

Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II)

2 Year
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
時間枠:2 Year

Incidence of Valve-related dysfunction requiring repeat procedure

2 Year
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
時間枠:2 year

Mean aortic gradient

2 year
Valve Hemodynamic Performance Metric - Effective Orifice Area
時間枠:2 year

Effective orifice area

2 year
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
時間枠:2 year

Degree of aortic regurgitation (transvalvular, paravalvular, total)

2 year
New York Heart Association (NYHA) Functional Classification
時間枠:2 Year

New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest).

Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.

Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.

Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.

Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.

2 Year
All-cause Mortality
時間枠:3 year

Percentage of participants with all-cause mortality

3 year
All Stroke
時間枠:3 year

Incidence of stroke (disabling and non-disabling)

3 year
Myocardial Infarction
時間枠:3 Year

Incidence of MI

3 Year
Incidence of Life-threatening Bleeding
時間枠:3 Year

Incidence of life-threatening bleeding:

  1. Fatal bleeding (BARC type 5) OR
  2. Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR
  3. Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR
  4. Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* (BARC type 3b)
3 Year
Incidence of Prosthetic Valve Endocarditis
時間枠:3 Year

Incidence of prosthetic valve endocarditis:

Any one of the following:

  1. Fulfillment of the following Duke criteria for definite endocarditis

    • Histologic and/or microbiologic evidence of infection at surgery or autopsy, or
    • 2 major criteria, or
    • 1 major criteria and 3 minor criteria, or
    • 5 minor criteria
  2. Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation

  3. Findings of abscess, pus, or vegetation involving the CoreValve™ Evolut™ PRO at autopsy

3 Year
Incidence of Prosthetic Valve Thrombosis
時間枠:3 Year

Incidence of Prosthetic valve thrombosis:

Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.

*Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis.

3 Year
Valve-related Dysfunction
時間枠:3 Year

Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II)

3 Year
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
時間枠:3 Year

Incidence of Valve-related dysfunction requiring repeat procedure

3 Year
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
時間枠:3 year

Mean aortic gradient

3 year
Valve Hemodynamic Performance Metric - Effective Orifice Area
時間枠:3 year

Effective orifice area

3 year
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
時間枠:3 year

Degree of aortic regurgitation (transvalvular, paravalvular, total)

3 year
New York Heart Association (NYHA) Functional Classification
時間枠:3 Year

New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest).

Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.

Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.

Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.

Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.

3 Year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jianan Wang, MD、Second Affiliated Hospital, Zhejiang University, School of Medicine

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年7月17日

一次修了 (実際)

2023年3月17日

研究の完了 (推定)

2028年5月15日

試験登録日

最初に提出

2021年7月8日

QC基準を満たした最初の提出物

2021年7月28日

最初の投稿 (実際)

2021年7月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年10月29日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • MDT18065EVR009

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する